Assenagon Asset Management S.A. Neurocrine Biosciences Inc Transaction History

Assenagon Asset Management S.A.

$54.8 Billion
Q1 2025

A detailed history of Assenagon Asset Management S.A. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 393,455 shares of NBIX stock, worth $40 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

393,455

Previous 26,140 1405.18%

Holding current value

$40 Million

Previous $3.57 Million 1119.62%

% of portfolio

0.08%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 15, 2025	BUY	$107.22 - $153.29 $39.4 Million - $56.3 Million	367,315 Added 1405.18%	393,455 $43.5 Million
Q4 2024 Jan 14, 2025	SELL	$111.62 - $139.44 $408,864 - $510,768	-3,663 Reduced 12.29%	26,140 $3.57 Million
Q3 2024 Oct 23, 2024	SELL	$114.58 - $153.15 $25.2 Million - $33.6 Million	-219,621 Reduced 88.05%	29,803 $3.43 Million
Q2 2024 Jul 18, 2024	SELL	$130.86 - $143.19 $11.6 Million - $12.6 Million	-88,313 Reduced 26.15%	249,424 $34.3 Million
Q1 2024 Apr 24, 2024	BUY	$130.4 - $143.74 $2.89 Million - $3.19 Million	22,177 Added 7.03%	337,737 $46.6 Million
Q4 2023 Jan 17, 2024	SELL	$106.07 - $132.76 $28.5 Million - $35.7 Million	-268,979 Reduced 46.02%	315,560 $41.6 Million
Q3 2023 Nov 06, 2023	BUY	$94.02 - $117.1 $30 Million - $37.4 Million	319,564 Added 120.6%	584,539 $65.8 Million
Q2 2023 Jul 25, 2023	BUY	$89.53 - $104.87 $15.6 Million - $18.3 Million	174,467 Added 192.76%	264,975 $25 Million
Q1 2023 Apr 18, 2023	SELL	$94.11 - $123.02 $11.1 Million - $14.5 Million	-117,923 Reduced 56.58%	90,508 $9.16 Million
Q4 2022 Jan 12, 2023	BUY	$106.72 - $127.06 $13.2 Million - $15.7 Million	123,613 Added 145.74%	208,431 $24.9 Million
Q3 2022 Oct 27, 2022	SELL	$92.03 - $107.81 $5.03 Million - $5.89 Million	-54,653 Reduced 39.19%	84,818 $9.01 Million
Q2 2022 Jul 27, 2022	BUY	$75.79 - $100.07 $9.52 Million - $12.6 Million	125,611 Added 906.28%	139,471 $13.6 Million
Q1 2022 Apr 25, 2022	SELL	$72.45 - $94.81 $5.21 Million - $6.82 Million	-71,965 Reduced 83.85%	13,860 $1.3 Million
Q4 2021 Feb 01, 2022	BUY	$79.65 - $106.22 $5.94 Million - $7.93 Million	74,634 Added 666.91%	85,825 $7.31 Million
Q3 2021 Oct 19, 2021	SELL	$86.18 - $99.03 $3.26 Million - $3.75 Million	-37,878 Reduced 77.19%	11,191 $1.07 Million
Q2 2021 Jul 15, 2021	BUY	$89.43 - $102.27 $4.1 Million - $4.69 Million	45,836 Added 1417.75%	49,069 $4.78 Million
Q1 2021 Apr 26, 2021	BUY	$87.57 - $119.4 $283,113 - $386,020	3,233 New	3,233 $314,000
Q3 2020 Oct 07, 2020	SELL	$96.16 - $135.15 $2.2 Million - $3.1 Million	-22,926 Closed	0 $0
Q2 2020 Jul 21, 2020	BUY	$85.09 - $130.36 $1.95 Million - $2.99 Million	22,926 New	22,926 $2.8 Million
Q4 2019 Jan 17, 2020	SELL	$86.8 - $118.57 $2.16 Million - $2.95 Million	-24,885 Closed	0 $0
Q3 2019 Oct 16, 2019	BUY	$83.82 - $101.5 $2.09 Million - $2.53 Million	24,885 New	24,885 $2.24 Million

Others Institutions Holding NBIX

# of Institutions

652

Shares Held

95.9M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $9.73B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.

Account

Assenagon Asset Management S.A. Neurocrine Biosciences Inc Transaction History